NDC product
Azilsartan medoxomil
NDC 70748-236 · Lupin Pharmaceuticals, Inc.
Key facts
| Product NDC | 70748-236 |
|---|---|
| Proprietary name | Azilsartan medoxomil |
| Nonproprietary name | Azilsartan medoxomil |
| Substances | AZILSARTAN KAMEDOXOMIL |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Lupin Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA214489 |
| Pharmacologic classes | Angiotensin 2 Receptor Blocker [EPC], Angiotensin 2 Type 1 Receptor Antagonists [MoA], Decreased Blood Pressure [PE] |
| Marketing start | May 14, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: